This site has been produced and fully funded by Apellis

Geographic atrophy is characterised by progressive and irreversible retinal cell loss1

With the ageing population, prevalence of late AMD is predicted to reach over 18 million cases by 2040.1,2

Learn more about GA
Geographic Atrophy

Geographic atrophy progression is continuous and irreversible2-5

Diagnosing geographic atrophy early and monitoring progression enables timely support to help manage the condition.

Learn about progression
Geographic Atrophy

Geographic atrophy can leave its mark on patients in more ways than one6-7

Patients with geographic atrophy can face a large emotional burden and loss of independence.6,7

Understand impact on patients
Geographic Atrophy

Geographic atrophy poses a significant burden to patients8

Geographic atrophy and advanced dry AMD are both terms used to describe the advanced form of dry age related macular degeneration (AMD), which is a leading cause of blindness worldwide.1,9

Over 5 million people worldwide are affected by geographic atrophy, with prevalence increasing with age.1 It has a significant and negative impact on vision and quality of life.8

About Apellis

We are a global biopharmaceutical company leveraging courageous science, creativity and compassion to deliver life-changing medicines. As leaders in the research of targeted therapies, we aim to develop new therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within haematology, nephrology, neurology and ophthalmology.

References

  1. Fleckenstein M, et al. Ophthalmology. 2018;125(3):369–390.
  2. Boyer DS, et al. Retina. 2017;37(5):819–835.
  3. Lindblad AS, et al. Arch Ophthalmol. 2009;127(9):1168–1174.
  4. Holz FG, et al. Ophthalmology. 2014;121(5):1079–1091.
  5. Sunness JS, et al. Ophthalmology. 2007;114(2):271–277.
  6. Apellis & The Harris Poll. 2022. Geographic Atrophy Insights Survey (GAINS).
  7. Sivaprasad S, et al. Ophthalmol Ther. 2019;8(1):115–124.
  8. Patel P, et al. Clin Ophthalmol. 2020;14:15–28.
  9. Gehrs KM, et al. Ann Med. 2006;38(7):450–471.

UK-GA-2300013     February 2024